Juan Carlos Miralles-López, Francisco-José Bravo-Gutierrez, Rubén Andújar-Espinosa, Manuel Castilla-Martínez, Cayetano Díaz-Chantar, Mercedes Ramírez-Hernández, Sheila Cabrejos-Perotti, Maria Jesús Avilés-Inglés, Inmaculada Ibarra-Calabuig, Miguel Henrique Reyes-Cotes, Manuel José Pajarón-Fernández, Roberto Bernabéu-Mora, Consuelo Alcalde-Rumayor, María Loreto Alemany-Francés, José Valverde-Molina, Virginia Pérez-Fernández
{"title":"Real-life effectiveness of tezepelumab in severe asthma.","authors":"Juan Carlos Miralles-López, Francisco-José Bravo-Gutierrez, Rubén Andújar-Espinosa, Manuel Castilla-Martínez, Cayetano Díaz-Chantar, Mercedes Ramírez-Hernández, Sheila Cabrejos-Perotti, Maria Jesús Avilés-Inglés, Inmaculada Ibarra-Calabuig, Miguel Henrique Reyes-Cotes, Manuel José Pajarón-Fernández, Roberto Bernabéu-Mora, Consuelo Alcalde-Rumayor, María Loreto Alemany-Francés, José Valverde-Molina, Virginia Pérez-Fernández","doi":"10.15586/aei.v53i2.1326","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tezepelumab is a human monoclonal antibody which inhibits the cytokine thymic stromal lymphopoietin and is effective in different asthma endotypes.</p><p><strong>Methods: </strong>This is a prospective, multicenter study of the Register of Severe Asthma of the Region of Murcia (RE-ASGRAMUR) Group performed under routine clinical practice conditions.</p><p><strong>Results: </strong>We present a series of 57 patients who completed at least 6 months of treatment with tezepelumab. The exacerbations decreased from a baseline mean of 2.63 in the previous year to a <i>mean annual rate</i> of 0.38 after 6 months of tezepelumab (85.6% decrease). The Asthma Control Test score increased by 5.3 points, and the Mini Asthma Quality of Life Questionnaire score increased by 0.94 points. Regarding lung function, we obtained a significant increase of 188 mL in forced expiratory volume in 1 s and 166 mL in forced vital capacity. Finally, type-2 (T2) biomarkers, such as eosinophils and nitric oxide, showed a significant decrease. We compared the results in patients with or without previous biological treatment as well as in patients with or without allergy sensitization, and we did not obtain significant differences in any variable.</p><p><strong>Conclusions: </strong>Tezepelumab is an effective treatment for severe asthma, lessening exacerbations, controlling the disease, and improving quality of life and lung function in patients with and without high T2 biomarkers, regardless of previous biological treatment.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 2","pages":"163-173"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v53i2.1326","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Tezepelumab is a human monoclonal antibody which inhibits the cytokine thymic stromal lymphopoietin and is effective in different asthma endotypes.
Methods: This is a prospective, multicenter study of the Register of Severe Asthma of the Region of Murcia (RE-ASGRAMUR) Group performed under routine clinical practice conditions.
Results: We present a series of 57 patients who completed at least 6 months of treatment with tezepelumab. The exacerbations decreased from a baseline mean of 2.63 in the previous year to a mean annual rate of 0.38 after 6 months of tezepelumab (85.6% decrease). The Asthma Control Test score increased by 5.3 points, and the Mini Asthma Quality of Life Questionnaire score increased by 0.94 points. Regarding lung function, we obtained a significant increase of 188 mL in forced expiratory volume in 1 s and 166 mL in forced vital capacity. Finally, type-2 (T2) biomarkers, such as eosinophils and nitric oxide, showed a significant decrease. We compared the results in patients with or without previous biological treatment as well as in patients with or without allergy sensitization, and we did not obtain significant differences in any variable.
Conclusions: Tezepelumab is an effective treatment for severe asthma, lessening exacerbations, controlling the disease, and improving quality of life and lung function in patients with and without high T2 biomarkers, regardless of previous biological treatment.
期刊介绍：
Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
